Can a common diabetes pill help transplant patients?
NCT ID NCT07228195
First seen Nov 15, 2025 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This study tests whether empagliflozin (Jardiance), a drug used for type 2 diabetes, can improve blood sugar control in people who have had an islet transplant and still have partial islet function. About 40 adults will receive either a placebo, 10 mg, or 25 mg of empagliflozin daily for 3 months. The main goal is to see if the drug increases the time their blood sugar stays in a healthy range.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin (Jardiance) 10 mg or 25 mg oral tablet
What this could lead to
If it works, this could help islet transplant recipients achieve better blood sugar control and reduce their insulin doses.
What could go wrong
This is a small, early pilot study with only 40 participants. The drug is already approved for type 2 diabetes but not specifically for this use, so results may not apply broadly.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.